Acute myeloid leukemia (AML) is a cancer that begins in the bone marrow, and often quickly progresses into the blood. Symptoms of the disease are often those that come about because of bone marrow failure, such as fatigue, infections, and bleeding.
When it comes to treating AML, there have been a handful of developments in the past year alone. In 2017, four new drugs were approved to treat the disease. Two of those drugs, Midostaurin and Enasidenib, are what Dr. Richard Stone, Clinical Director of the Adult Leukemia Program at Dana-Farber Cancer Institute, calls “true targeted therapies.”
Read MoreLearn more about SurvivorNet's rigorous medical review process.